Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Otsuka to acquire PDL's Busulfex

Otsuka (Tokyo:4768) will acquire IV Busulfex busulfan from PDLI for $200 million

Read the full 120 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE